The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and-7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1 beta Activation

James E Vince; Dominic De Nardo; Wenqing Gao; Angelina J Vince; Cathrine Hall; Kate McArthur; Daniel Simpson; Swarna Vijayaraj; Lisa M Lindqvist; Philippe Bouillet; Mark A Rizzacasa; Si Ming Man; John Silke; Seth L Masters; Guillaume Lessene; David CS Huang; Daniel HD Gray; Benjamin T Kile; Feng Shao; Kate E Lawlor

Journal article

The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and-7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1 beta Activation

James E Vince, Dominic De Nardo, Wenqing Gao, Angelina J Vince, Cathrine Hall, Kate McArthur, Daniel Simpson, Swarna Vijayaraj, Lisa M Lindqvist, Philippe Bouillet, Mark A Rizzacasa, Si Ming Man, John Silke, Seth L Masters, Guillaume Lessene, David CS Huang, Daniel HD Gray, Benjamin T Kile, Feng Shao, Kate E Lawlor

Cell Reports | CELL PRESS | Published : 2018

DOI: 10.1016/j.celrep.2018.10.103

University of Melbourne Researchers

Kate Lawlor Author Medical Biology (W.E.H.I.)

Dominic de Nardo Author Medical Biology (W.E.H.I.)

Guillaume Lessene Author Medical Biology (W.E.H.I.)

Philippe Bouillet Author Medical Biology (W.E.H.I.)

James Vince Author Medical Biology (W.E.H.I.)

Grants

Awarded by National Health and Medical Research Project

Awarded by Australian Government IRISS

Funding Acknowledgements

We thank for technical assistance: R. Crawley, L. Wilkins, S. Oliver, and L. Johnson for animal care; S. Monard and staff for flow cytometric sorting; K. Rogers and staff from the Centre for Dynamic Imaging for assistance; TetraLogic Pharmaceuticals for Smac-mimetic compounds; Lorraine O'Reilly for the generous supply of in-house antibodies; Andreas Strasser, Kerstin Brinkmann, and Gemma Kelly (WEHI) and Vishva Dixit (Genentech) for gene targeted mice; and Jennifer M. Chambers for epi-silvesterol synthesis. This work was supported by National Health and Medical Research Project grants (1101405, 1145788, 1099262, 1078763, 1046010, 1051506, and 1127885), fellowships (1052598, 1141466, 1016647, 1090236, 1107149, and 1042629), and program grants (461221 and 1113133), an Australian Federal Government Postgraduate Award, and the DHB Foundation, managed by ANZ Trustees. S.L.M. acknowledges additional funding from the Sylvia and Charles Viertel Foundation, an HHMI-Wellcome International Research Scholarship, and GlaxoSmithKline. This work was also supported by operational infrastructure grants through the Australian Government IRISS (9000220) and the Victorian State Government OIS.